XFOR logo

XFOR

X4 Pharmaceuticals Inc.

$3.56
+$0.18(+5.33%)
49
Overall
80
Value
18
Tech
--
Quality
Market Cap
$36.62M
Volume
292.30K
52W Range
$1.35 - $26.82
Target Price
$8.70
Order:

Income Statement

MetricTrendChart
2018
Dec
2019
Dec
2020
Dec
2021
Dec
2022
Dec
2023
Dec
2024
Dec
REVENUE
Total Revenue
$3.5M$14.0K$3.0M$196.0K$196.0K$195.0K$2.6M
Total Revenue
$3.5M$14.0K$3.0M--$196.0K$195.0K$2.6M
COST OF GOODS SOLD
Cost of Revenue
------------$797.0K
GROSS PROFIT
Gross Profit
$3.5M$14.0K$3.0M--$196.0K$195.0K$1.8M
OPERATING EXPENSES
Operating Expenses
$29.1M$51.7M$62.9M$85.1M$87.6M$107.5M$143.2M
Research & Development
$20.3M$30.2M$41.9M$50.6M$61.1M$72.0M$81.6M
Research Expense
$20.3M$30.2M$41.9M$50.6M$61.1M$72.0M$81.6M
Selling, General & Administrative
$8.7M$17.6M$20.9M$24.7M$27.0M$35.5M$61.5M
General & Administrative Expenses
$8.7M$17.6M$20.9M$24.7M$27.0M$35.5M$61.5M
Salaries & Wages
$-759.0K------------
Depreciation & Amortization
$-103.0K$103.0K$351.0K$499.0K$513.0K$419.0K--
Depreciation & Amortization
$-103.0K$592.0K$351.0K$499.0K------
Amortization
--$27.1M$27.1M$17.4M$17.4M$17.4M$17.4M
Other Operating Expenses
$-49.4M$949.0K$1.4M$2.1M------
OPERATING INCOME
Operating income
$-29.1M$-51.7M$-59.9M$-85.1M$-87.6M$-107.5M$-36.4M
EBITDA
$-32.5M$-50.6M$-58.9M$-84.5M$-89.3M$-94.9M$-27.6M
NON-OPERATING ITEMS
Interest Expense (Non-Operating)
$3.7M$2.1M$2.7M$3.6M$4.0M$5.8M$8.8M
Intinc
$236.0K$1.2M$273.0K$10.0K$219.0K$4.6M$5.8M
Net Non-Operating Interest Income/Expense
$-3.5M$-950.0K$-2.4M$-3.6M$-3.8M$-1.2M$-3.0M
Gain on Sale of Securities
--$183.0K$-437.0K$-366.0K$1.7M$7.1M$1.9M
Other Income/Expense
$3.6M$4.1M$-306.0K$-60.0K$-2.0M$-7.6M$-107.3M
Other Special Charges
$-3.6M$-4.2M$743.0K$426.0K$-3.7M$554.0K$105.3M
SPECIAL ITEMS
Restructring And Mn A Income
$76.2M$57.8M----------
Special Income Charges
$-76.2M$-57.8M--$-9.8M------
Impairment of Capital Assets
------$9.8M------
PRE-TAX INCOME
EBIT
$-32.6M$-50.7M$-59.3M$-85.0M$-89.8M$-95.3M$-28.4M
Pre-Tax Income
$-36.3M$-52.8M$-62.0M$-88.7M$-93.8M$-101.1M$-37.1M
INCOME TAX
Tax Provision
----$148.0K$17.0K$28.0K$78.0K$300.0K
NET INCOME
Net Income
$-36.3M$-52.8M$-62.1M$-88.7M$-93.9M$-101.2M$-37.5M
Net Income (Continuing Operations)
$-36.3M$-52.8M$-62.1M$-88.7M$-93.9M$-101.2M$-37.5M
Net Income (Discontinued Operations)
$-36.3M$-52.8M$-62.1M$-88.7M$-93.9M$-101.2M$-37.5M
Net Income (Common Stockholders)
$-36.3M$-53.4M$-62.1M$-102.6M$-96.4M$-101.2M$-37.5M
TOTALS
Total Expenses
$29.1M$51.7M$62.9M$85.1M$87.6M$107.5M$144.0M
SHARE & EPS DATA
Average Shares Outstanding
$79.5K$384.3K$669.2K$858.3K$2.1M$5.9M$201.1M
Average Shares Outstanding (Diluted)
$79.5K$384.3K$669.2K--$2.1M$5.9M$201.1M
Shares Outstanding
$81.4K$537.8K$579.5K$1.0M$4.1M$5.6M$173.7M
Basic EPS
--$-138.9$-92.7$-119.7$-45.6$-17.1$-0.19
Basic EPS (Continuing Operations)
--$-138.9$-92.7$-119.7$-45.6$-17.1$-0.19
Diluted EPS
$-541.8$-138.9$-92.7$-119.7$-45.6$-17.1$-0.19
Diluted EPS (Continuing Operations)
$-541.8------$-45.6$-17.1$-0.19
OTHER METRICS
Accrued Preferred Stock Dividends
$22.0K----$13.9M------
Acquisition Expense
--$592.0K----------
Other Gand A
$8.7M$17.6M$20.9M$24.7M$27.0M$35.5M$61.5M
Otherunder Preferred Stock Dividend
$22.0K----$13.9M------
Preferred Stock Dividends
$22.0K----$13.9M------
Rent And Landing Fees
$-1.3M------------
Restruct
$76.2M$57.8M----------

Financial data is updated quarterly and may not reflect the most recent earnings.

ABCD
1SymbolPriceChangeVol
2XFOR$3.56+5.3%292.30K
3
4
5
6

Get X4 Pharmaceuticals Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.